Phase II Adaptive Deep Brain Stimulation for Obsessive-Compulsive Disorder
Key facts
- Who runs it
- Baylor College of Medicine
- Where
- Houston, Pittsburgh, and Providence, United StatesSee the 3 sites
- Trial code
- Status
- Active, not recruiting
- People taking part
- 5 people enrolled
- Started
- 1 Jul 2021
- Expected to end
- 30 Jul 2027
- Type of study
- Interventional, 2 groups
- Treatments tested
- Summit RC+S System with ECoG Paddles
- One Month Blinded Discontinuation Period:
- Record updated
- 2 September 2026
Who can take part
- Age
- 18 years to 70 years
- Sex
- Women and men
- Healthy volunteers
- Can take part
Show the full registry criteria (19)Hide the full registry criteria
Who can take part
- Signed informed consent prior to any study specific procedures being performed
- Male or female between ages 21 and 70
- At least a five-year history of treatment-refractory OCD that causes substantial subjective distress and impairment in functioning
- A primary diagnosis of OCD with Y-BOCS minimum score of 28
- Failed an adequate trial of at least three of the following SSRIs: Fluoxetine; fluvoxamine; citalopram; escitalopram; sertraline; paroxetine
- Failed or could not tolerate an adequate trial of clomipramine
- Failed augmentation of one or more of the aforementioned drugs with at least one of the following antipsychotics: haloperidol; risperidone; quetiapine; ziprasidone; aripiprazole
- Failed an adequate trial of CBT for OCD, defined as 25 hours of documented exposure and response prevention (ERP) by an expert therapist
- Stable psychotropic medical regimen for the month preceding surgery
Who cannot take part
- Lifetime diagnosis of psychotic disorders such as schizophrenia
- Any Neurological/Medical condition that makes the subject, in the opinion of the surgeon, a poor candidate
- Pregnant (confirmed by serum pregnancy test on females of child bearing age) or plans to become pregnant in the next 24 months
- Inability or refusal to give informed consent
- Alcohol or substance abuse/dependence within 6 months, excluding nicotine
- Deemed at high risk of suicidal behavior or impulsivity, per clinical opinion assessments
- Need for Diathermy
- Contraindications to MRI
- Contraindications to MEG
- Subject is determined to not be appropriate for this study based on the medical expertise of the investigator
Where in United States
- Baylor College of MedicineHouston, United States
- University of PittsburghPittsburgh, United States
- Brown UniversityProvidence, United States
About the trial
What the trial wants to find out
This research study is for participants that have been diagnosed with intractable Obsessive -compulsive disorder (OCD). OCD is a persistent and oftentimes disabling disorder marked by unwanted and distressing thoughts (obsessions) and irresistible repetitive behaviors. OCD affects 2-3% of the US population, and is responsible for substantial functional impairment and increased risk of early death.
Read full original descriptionShow less
The only established first-line treatments for OCD are cognitive-behavioral therapy (CBT) with exposure and response prevention and certain medications. About 30-40% of patients fail to respond and few experience complete symptom resolution. Up to 25% of patients have difficulty tolerating CBT and the risk of relapse after therapies remains large. For the most severe cases, neurosurgery (surgery in the brain), has long been the option of last resort.
In this study the investigators want develop an adaptive Deep Brain Stimulation (aDBS) system to use in subjects with intractable (hard to control) OCD. Deep brain stimulation (DBS) remains investigational for OCD patients and is not considered standard therapy. DBS involves the surgical implantation of leads and electrodes into specific areas of the brain, which are thought to influence the disease. A pack implanted in the chest, called the neurotransmitter, keeps the electrical current coursing to the brain through a wire that connects the neurotransmitter and electrodes. It is believed DBS may restore balance to dysfunctional brain circuitry implicated in OCD. The goal of this study is to enhance current approaches to DBS targeting in the brain and to use a novel approach to find a better and more reliable system for OCD treatment.
This current research protocol will focus on the completion of Phase II which will implant the RC+S system with ECoG paddles in 5 subjects.
The 2 groups in the trial
- Summit RC+S DBS Implant for OCDTreatment being tested
All subjects will receive surgical implantation of RC+S DBS system with ECoG paddles
Treatment: Summit RC+S System with ECoG Paddles
- One Month Blinded Discontinuation PeriodTreatment being tested
The subject and Independent Evaluators are blinded to timing of discontinuation. In all cases, the sequence will be as follows in one-week segments: 100% Active, 50% Active, Sham and Sham. Subjects will be seen weekly. Amplitude will be reduced by 50% at start of week 2 and turned off at start of week 3. Subjects will be told that DBS will be discontinued at some point during the 4 weeks. The purpose of the 50% initial reduction is to minimize rebound effects. The programmer (not the PI in this case) will be open to the design and perform "sham" activation as described previously. Relapse is defined as a 25% increase of the Y-BOCS over two consecutive visits compared to discontinuation baseline
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Development of Adaptive Deep Brain Stimulation (aDBS) for the Treatment of Intractable Obsessive-Compulsive Disorder (OCD) Phase II Using Summit RC+S System With ECoG Paddles
- Publications
- High Beta Power in the Ventrolateral Prefrontal Cortex Indexes Human Approach Behavior: A Case Study.The Journal of neuroscience : the official journal of the Society for Neuroscience, 2025
- Record updated
- 2 September 2026